SCL Science

SCL Science EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of SCL Science (246960.KQ) as of Nov 18, 2026 is -29.43. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -24.52 — a change of 20.04% (lower).

EV/EBITDA

-29.43

YoY

20.04%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of SCL Science is 2025 -29.43 . EV/EBITDA (Enterprise Value to EBITDA) of SCL Science was 2024 -24.52 . It decreases by 20.04% lower compared to the previous year.

The SCL Science EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-27.18 KRW
Jan 1, 2019
-17.06 KRW
Jan 1, 2020
-26.80 KRW
Jan 1, 2021
-19.36 KRW
Jan 1, 2022
-17.08 KRW
Jan 1, 2023
-11.36 KRW
Jan 1, 2024
-24.52 KRW
Jan 1, 2025
-29.43 KRW
The SCL Science EV/EBITDA history
YEAREV/EBITDAYoY
-29.43+20.04%
-24.52+115.90%
-11.36-33.49%
-17.08-11.81%
-19.36-27.75%
-26.80+57.08%
-17.06-37.22%
-27.18-0.60%
-27.34-37.75%
-43.93-27.48%
-60.57—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

EV/EBITDA (Enterprise Value to EBITDA) of SCL Science is -29.43 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of SCL Science changed from -24.52 to -29.43, representing a 20.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) SCL Science since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s SCL Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SCL Science

All Key Metrics — SCL Science